0710-0014

Seraseq™ Circulating Tumor DNA-I Reference Material (AF1.2)

/contentassets/173aaa557a5c42878b61641f980ee019/seracare_ctdna_products2.jpg
  • Size

    1 × 5 mL

  • List Price

    Contact Us

  • Unit

    EA

  • Inventory Status

    In Stock

Description

Seraseq Circulating Tumor DNA-I Reference Material (AF1.2) is a set of 9 mutations (single-nucleotide variants in addition to insertion/deletions), fragmented and stabilized then mixed into a plasma-like matrix at a 1.2% allele frequency. 

  • Mutations and wild-type allele are fragmented to an average size of 170 base-pairs
  • Proprietary stabilization technology in defined MatriBase matrix
  • GM24385 'wild-type' background yields no extraneous mutation artifacts
  • Single-tube 5mL format contains 60ng of extractable nucleic acid
  • Manufactured in cGMP compliant, ISO 9001 and ISO 13485 certified facilities 

Seraseq Circulating Tumor DNA-I Reference Material (AF1.2). - List of Mutations
The presence of the mutation in a particular assay depends upon the enrichment strategy and sequencing platform used.

The Seraseq Circulating Tumor DNA-I (AF1.2) Reference Material is formulated for use with targeted next-generation sequencing (NGS) assays, real-time quantitative PCR (qPCR) or digital PCR (dPCR) assays that screen for circulating tumor DNA (ctDNA) in a cell-free plasma sample. The Seraseq Circulating Tumor DNA-I (AF1.2) Reference Material is intended as a quality material for translational oncology researchers, assay developers, and clinical pathology laboratories, and monitors sample purification, library preparation, and sequencing (if using an NGS-based assay), and detection performance.

For research use only. Not for use in diagnostic procedures.